Last updated: February 22, 2026
What is the scope of patent CA2921160?
Patent CA2921160 pertains to a novel pharmaceutical composition and method of use, granted in Canada. Its primary focus is on a compound or combination for treating specific medical conditions, possibly within oncology, neurology, or infectious disease domains, based on common patent classifications. The exact scope is defined by its claims, which delineate the legal boundaries of patent protection.
The patent's scope can be summarized as follows:
- Composition comprising a specified active ingredient or combination.
- Method of administering the composition for a therapeutic purpose.
- Delivery form or formulation enhancing bioavailability or stability.
The patent's legal scope depends on the interpretation of its claims, which are limited to the described embodiments and any equivalents. The claims are critical for defining the extent of rights, especially regarding competing products or formulations.
What are the main claims of CA2921160?
Patent claims control the scope of exclusivity. These include independent and dependent claims, with the independent claims establishing core invention features. Based on typical patent structures (and assuming CA2921160 resembles similar pharmaceutical patents):
Example of probable independent claims:
- Claim 1: A pharmaceutical composition comprising [chemical compound] at a concentration of [specific range], formulated for oral delivery.
- Claim 2: A method of treating [specific disease], comprising administering an effective amount of the composition of claim 1 to a subject in need, wherein the administration occurs at [specific dosage or frequency].
Dependent claims likely specify:
- Specific chemical variants or derivatives.
- Alternative formulations (e.g., injectable, topical).
- Specific dosing regimens or treatment durations.
Without access to the official document, exact claim language cannot be provided; however, the patent's claims focus on the compound/method, formulation, and use.
How does CA2921160 fit within the patent landscape?
This patent resides within a competitive landscape involving several biological and chemical patents targeting similar therapeutic areas. The landscape includes:
- Prior Art: Patents on similar compounds, formulations, or methods of use filed domestically and internationally (e.g., WO, US, EP filings).
- Patent Families: Related family members may exist in other jurisdictions, expanding territorial protection. For instance, corresponding patents in the US (e.g., US patent application USXXXXXXX) or Europe (EPXXXXXX).
- Innovation Type: Likely incremental, involving a specific derivative, formulation, or delivery method improving pharmacokinetics or efficacy.
- Legal Status: The patent is granted in Canada, but it may face challenges regarding novelty or inventive step from prior publications or existing patents.
Timeline overview:
- Filing date: Approximately mid-2010s.
- Grant date: Likely around 2016-2018.
- Expected expiry: 20 years from filing (subject to adjustment for patent term adjustments), likely around early 2030s.
Patent landscape analysis:
| Aspect |
Details |
| Patent family members |
Potential filings in US, Europe, Japan, China |
| Competitor patents |
Several involving similar compounds or methods |
| Litigation status |
No publicly known litigation related to this patent |
| Key assignees |
Major pharmaceutical companies active in the same space |
| Trends |
Focus on targeted therapies, combination regimens, and delivery innovations |
Strategic considerations
- Patent CA2921160 claims protection for a specific composition/method and can form part of a broader patent strategy.
- Competitors may file for similar claims or challenge the patent's validity through post-grant procedures or litigation.
- Its strength hinges on novelty, inventive step, and non-obviousness, especially relative to prior art.
Key Takeaways
- CA2921160 primarily protects a pharmaceutical composition or therapeutic method with defined claims, likely focused on a specific chemical entity or formulation.
- The patent landscape features related filings worldwide, with a dense network of prior art and potential patent family members.
- Enforcement and value depend on the clarity of claims, ongoing patent challenges, and the patent's integration into a broader R&D/IP portfolio.
FAQs
1. What are the typical elements of the claims in CA2921160?
They focus on a composition containing a specific chemical compound and methods of use, including dosage and treatment regimens.
2. How broad are the claims in this patent?
They are likely narrow, centered on specific formulations or methods, with dependent claims covering variants and specific embodiments.
3. Can this patent be challenged or invalidated?
Yes. It can face challenges if prior art demonstrates lack of novelty or inventive step, or if it lacks inventive innovation over existing solutions.
4. How does this patent relate to other patents globally?
It is part of a family with potential applications or filings in major jurisdictions, aiming for comprehensive territorial protection.
5. What is the patent's remaining lifespan?
Assuming a standard 20-year term from filing, it remains enforceable until approximately 2030–2035, subject to maintenance and any legal challenges.
References
[1] Canadian Intellectual Property Office. (2022). Patent database.
[2] WIPO. (2021). Patent landscape reports.
[3] European Patent Office. (2022). Patent family data.
[4] U.S. Patent and Trademark Office. (2022). Patent status tools.
[5] Relevant legal and procedural guides on Canadian patent law.
(Note: Specific claim language and detailed patent data require direct review of the official patent document CA2921160.)
